Viridian Therapeutics, Inc. announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease —including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, to be held April 23-27, 2023, in New Orleans, Louisiana.
April 20, 2023
· 7 min read